Unknown Author
January 23, 2026
Sidley Represents Capricor Therapeutics in US$23 Million Common Stock Offering

1 min
AI-made summary
- Sidley advised Capricor Therapeutics, Inc
- on the issuance and sale of 4,935,621 shares of common stock in a registered direct offering, generating estimated gross proceeds of approximately US$23 million
- Each share was sold with a warrant to purchase one share of common stock, exercisable six months after issuance and expiring seven years later
- The Sidley deal team was led by Rob R
- Carlson, Nick DeAngelis, and Hannah M
- Brown, with additional team members listed.
Sidley represented Capricor Therapeutics, Inc. in connection with the issuance and sale of 4,935,621 shares of common stock in a registered direct offering for estimated gross proceeds of approximately US$23 million. The shares were sold with a warrant to purchase one share of common stock exercisable six months after issuance and expiring seven years from the date of issuance.
The deal team was led by Rob R. Carlson, Nick DeAngelis, and Hannah M. Brown, and included Torrey Cope, Barbara Endres, Carlton Fleming, Dan O’Shea, Carla Teodoro, Jim Mendenhall, and Jen Fernandez.~~Sidley represented Capricor Therapeutics, Inc. in connection with the issuance and sale of 4,935,621 shares of common stock in a registered direct offering for estimated gross proceeds of approximately US$23 million. The shares were sold with a warrant to purchase one share of common stock exercisable six months after issuance and expiring seven years from the date of issuance.
The deal team was led by Rob R. Carlson, Nick DeAngelis, and Hannah M. Brown, and included Torrey Cope, Barbara Endres, Carlton Fleming, Dan O’Shea, Carla Teodoro, Jim Mendenhall, and Jen Fernandez.
Article Author
Unknown Author
The Sponsor
